Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Hudson Health Sciences was a biopharmaceutical company founded in 2002 that specialized in the development of targeted cancer therapies and supportive care products. The company is best known for its evolution into Hana Biosciences and subsequently Talon Therapeutics, which focused on utilizing the Optisome liposomal delivery platform to enhance the efficacy and safety of existing chemotherapeutic agents. Its lead product, Marqibo (vincristine sulfate liposome injection), received FDA approval in 2012 for the treatment of adult Philadelphia chromosome-negative acute lymphoblastic leukemia. The company's assets and operations were eventually acquired by Spectrum Pharmaceuticals in 2013.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Hudson Health Sciences.